Pepticom
Tel Aviv, Israel· Est.
AI‑powered platform that designs next‑generation therapeutic peptides, starting with an oral IL‑17 inhibitor for psoriasis.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered platform that designs next‑generation therapeutic peptides, starting with an oral IL‑17 inhibitor for psoriasis.
ImmunologyDermatology
Technology Platform
A proprietary AI platform that fuses reinforcement learning, first‑principles modeling, and structural data integration to generate and optimize peptide therapeutics across a 10⁸⁰‑size chemical space.
Opportunities
The platform can be applied to a broad range of unmet‑need targets, enabling rapid entry into high‑value markets such as autoimmune diseases and oncology.
Risk Factors
Key risks include the translation of AI‑predicted peptide properties into clinical efficacy and safety, as well as competition from larger firms developing similar AI‑driven peptide pipelines.
Competitive Landscape
Pepticom differentiates itself through ultra‑fast, reinforcement‑learning‑driven design and extensive non‑natural amino‑acid chemistries, setting it apart from traditional peptide discovery companies and emerging AI biotech platforms.